Burosumab 30mg/1ml solution for injection vials
NHS hospitals in England used £59,205,696 of indicative cost of Burosumab 30mg/1ml solution for injection vials in the 12 months to July 2026, about 0.2% of all hospital medicines spend. That is down 5.5% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Burosumab 30mg/1ml solution for injection vials: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to July 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Burosumab 30mg/1ml solution for injection vials most
By indicative cost over the 12 months to July 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| University College London Foundation Tr | £11,516,208 |
| Oxford University Hospitals Nhs Ft | £7,414,176 |
| Royal National Ortho.hospital Trust | £6,220,368 |
| Univ Hpls Bristol Nhs Foundation Trust | £6,112,656 |
| Alder Hey Childrens Nhs Foundation Trust | £4,694,448 |
| Manchester University Nhs Ft | £3,823,776 |
| Sheffield Teaching Hospitals Nhs Trust | £3,294,192 |
| The Newcastle Upon Tyne Hpl Nhs Found Tr | £2,540,208 |
| Nottingham University Hospitals Trust | £2,495,328 |
| Sheffield Children's Nhs Ft | £1,759,296 |
The primary-care picture
No confident match to a community-dispensed medicine was found for this product, so no primary-care comparison is shown. SCMD products are recorded at product level, which does not always map cleanly to a BNF substance.